Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Candel Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $26.6 million for Q2 2021.
- For Q2 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $26.6 million; the TTM value through Jun 2021 reached $26.6 million, changed 0.0%, while the annual FY2020 figure was $22.5 million, N/A changed from the prior year.
- Preferred Stock Liabilities for Q2 2021 was $26.6 million at Candel Therapeutics, roughly flat from $26.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $26.6 million in Q2 2020 and bottomed at $22.5 million in Q3 2020.